FIG. 1




FIG. 2



Part 1 Dose Escalation
Part 1A - Monotherapy Q3W Dose Escalation
0.15mg/kg
0.5mg/kg
1.2mg/kg
2mg/kg
3mg/Kg
4mg/kg
5mg/kg
mTPI n=2-4
Part 1B - Combination Q2W Dose Escalation
2mg/kg
2.7mg/kg
3.3mg/kg
Part 2 Dose Escalation
Part 2A - Monotherapy Q3W Expansion Arm
Arm M1: ≥3L BC HER2+, N=20
(HER2 IHC3+ or ISH+)
PF-06804103 3.0 mg/kg
Arm M2: ≥3L BC HER2+, N=20
(HER2 IHC3+ or ISH+)
PF-06804103 4.0 mg/kg
Arm M3: ≥2L BC HR+ HER2-, N=20
HER2- (HER2 IHC 1+ or ISH 2+ ISH-)
PF-06804103 4.0 mg/kg
Part 2A - Combination Q2W Expansion Arm
Arm C1: 1L BC HR+ HER2-, N=20
HER2- (HER2 IHC 1+ or IHC 2+ ISH-)
PF-06804103+Palbociclib+Letrozole
Monotherapy Expansion Arm Total N=60
Combination Expansion Arm Total N=20,
plus~6-8 pts in dose escalation

FIG. 3



Best % Change from Baseline in Sum of Diameters for Target Lesions
80
60
40
20
0
-20
-40
-60
-80
-100
-120
Individual Patients
n=29
Gastric or esophageal junction cancer
Breast cancer
PF-06804103
Treatment Group:
A 0.15 mg/kg
B 0.5 mg/kg
C 1.2 mg/kg
D 2.0 mg/kg
E 3.0 mg/kg
F 4.0 mg/kg
G 5.0 mg/kg

FIG. 4A




Serum PF-06380101 Concentration (ng/mL)
1000
100
10
1
0.1
0.01
0
7
14
21
Nominal Time Post Dose (Days)
A
B
C
D
E
F
G
PF-06804103
Treatment Group:
A 0.15 mg/kg
B 0.5 mg/kg
C 1.2 mg/kg
D 2.0 mg/kg
E 3.0 mg/kg
F 4.0 mg/kg
G 5.0 mg/kg

FIG. 4B


Serum PF-06380101 Concentration (ng/mL)
10
1
0.1
0.01
0
7
14
21
Nominal Time Post Dose (Days)
A
B
C
D
E
F
G
PF-06804103
Treatment Group:
A 0.15 mg/kg
B 0.5 mg/kg
C 1.2 mg/kg
D 2.0 mg/kg
E 3.0 mg/kg
F 4.0 mg/kg
G 5.0 mg/kg